C-peptide Concentrations in Type 2 Diabetes Treated With Insulin; is it Time to Revise the Treatment of Type 2 Diabetes
|ClinicalTrials.gov Identifier: NCT04005261|
Recruitment Status : Completed
First Posted : July 2, 2019
Last Update Posted : July 2, 2019
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Treated With Insulin||Diagnostic Test: C-peptide concentrations|
|Study Type :||Observational|
|Actual Enrollment :||249 participants|
|Official Title:||Is it Time to Revise Type 2 Diabetes Treatment: C-peptide Concentrations in Type 2 Diabetes Treated With Insulin|
|Actual Study Start Date :||November 1, 2018|
|Actual Primary Completion Date :||February 1, 2019|
|Actual Study Completion Date :||March 1, 2019|
patients with type 2 diabetes treated with insulin
Patients with type 2 diabetes who have been using insulin for at least six months.
They should be older than 18 years The patients should be presented to the Diabetes Outpatient Clinics of Istanbul Medeniyet University Goztepe Training and Research Hospital
Diagnostic Test: C-peptide concentrations
The patients will be grouped by their C-peptide concentrations
- The incidence of adequate, borderline and insufficient beta cell reserves assessed by the fasting C-peptide concentrations [ Time Frame: 3 months ]Fasting C-peptide concentrations will be measured in patients with type 2 diabetic patients using insulin as a monotherapy or as part of combination therapy and the patients will be grouped as patients with adequate beta cell reserves, patients with borderline beta cell reserves and patient with insufficient beta cell reserves.
- Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings [ Time Frame: 3 months ]Correlations of fasting C-peptide concentrations with patients characteristics and biochemical findings, especially the components of metabolic syndrome.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04005261
|IMU Goztepe Education and Research Hospital|
|Principal Investigator:||Ayşe N Erbakan, MD||IMU Doctoral program|
|Study Director:||Mehmet Uzunlulu, Prof||IMU Goztepe Education and Research Hospital|